In two additional breast cancer cell lines—SK-BR-3 (HER2-overexpressing) and MCF7 (low-HER2-expressing)—r40 demonstrated anti-proliferative activity comparable to that of trastuzumab and pertuzumab (Fig 2B). This evidence concerns the gene ERBB2 and breast carcinoma.